Transcript
NashBio partners with a wide range of clients, from large pharmaceutical companies to biotech startups, offering tailored solutions regardless of their level of sophistication in data science. Working with NashBio provides clients with a “white-glove” service, guiding them through R&D challenges and helping them achieve their goals.
One of the major advantages of partnering with NashBio lies in its focus on genetics. Peer-reviewed studies and trials have demonstrated that leveraging genetic data in clinical trials significantly increases the probability of success in Phase 2 trials. Additionally, NashBio provides access to longitudinal, richly detailed clinical data. This allows clients to see a comprehensive “movie” of a patient’s journey rather than a static snapshot, offering deeper insights into disease progression and treatment outcomes.
For pharmaceutical companies, the investment required to bring a new drug to market involves substantial risk. By engaging with NashBio and utilizing its high-quality data, companies can mitigate some of this risk, ultimately paving the way for new drug discoveries and breakthroughs in healthcare.
